Mitre Medical Corp CEO John MacMahon tells Proactive the privately-held group is developing a less invasive and safer approach to treat functional mitral valve regurgitation (MR) in patients with moderate to severe MR.
MacMahon says the group recently announced one-year results of the group’s Mitral Touch in European patients, and looks forward to bringing the technology to the US within four different clinical sites.
“Our team preclinical training was outstanding. We are screening for first patients for the ENRAPT-US Study to provide a less-invasive epicardial repair.’ Dr. Rob Smith II, Principal investigator in the study stated, “We were impressed by the ease of use and visibility in the mini-thoracotomy delivery. That is definitely the least invasive approach, and I can see it for dilated heart failure patients and failed MitraClips.” ~ Dr. Robert Smith
“Great having the team from Baylor, Scott, and White trained on our full complement of beating heart right and left-sided devices. ” Said Dr. Isaac George, MD, Mitre Scientific Advisor and Surgical Director of the Heart Valve Center at New York-Presbyterian / Columbia Hospital, “Watching them perform the first tricuspid implant was exciting. The team has leveraged all the mitral learning into a fully adjustable tricuspid repair that can be performed in minutes.” ~ Dr. Issac George